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Abstract:
Herein is reported the synthesis of two Au(III) complexes bearing the
(R,R)-(–)-2,3-Bis(tert-butylmethylphosphino)quinoxaline (R,R-QuinoxP*) or (S,S)-(+)-2,3-Bis(tertbutylmethylphosphino)quinoxaline (S,S-QuinoxP*) ligands. By reacting two stoichiometric equivalents
of HAuCl4 .3H2 O to one equivalent of the corresponding QuinoxP* ligand, (R,R)-(–)-2,3Bis(tert-butylmethylphosphino)quinoxalinedichlorogold(III) tetrachloroaurates(III) (1) and (S,S)(+)-2,3-Bis(tert-butylmethylphosphino)quinoxalinedichlorogold(III) tetrachloroaurates(III) (2) were
formed, respectively, in moderate yields. The structure of (S,S)-(+)-2,3-Bis(tert-butylmethylphosphino)
quinoxalinedichlorogold(III) tetrachloroaurates(III) (2) was further confirmed by X-ray crystallography.
The antiproliferative activities of the two compounds were evaluated in a panel of cell lines and
exhibited promising results comparable to auranofin and cisplatin with IC50 values between 1.08
and 4.83 µM. It is noteworthy that in comparison to other platinum and ruthenium enantiomeric
complexes, the two enantiomers (1 and 2) do not exhibit different cytotoxic effects. The compounds
exhibited stability in biologically relevant media over 48 h as well as inert reactivity to excess
glutathione at 37 ◦ C. These results demonstrate that the Au(III) atom, stabilized by the QuinoxP*
ligand, can provide exciting compounds for novel anticancer drugs. These complexes provide a new
scaffold to further develop a robust and diverse library of chiral phosphorus Au(III) complexes.
Keywords: gold; cisplatin; auranofin; antiproliferative; anticancer activity; ligands; QuinoxP*

1. Introduction
The therapeutic application of metals is an ancient practice, dating back to the discovery of metals
by man. Synthesis and application of metal complexes took a dramatic shift since the work of Rosenberg,
Van Camp and Krigas on cisplatin were published [1]. This discovery is commonly referred to as the
bedrock of metals in medicine [2]. Over the years, a few metal-based drugs such as Pepto-Bismol®
(Bismuth subsalicylate), Camcolit (Li2 CO3 ), Flamazine (Silver sulfadiazene) and Auranofin (Gold)
have been approved for the treatment of ulcer, manic depression, bacterial infection and arthritis [3–5],
respectively. Recent studies on auranofin has been geared toward repurposing the drug as an anticancer
agent [6,7].
Cancer is a leading cause of death globally, and the number of new cases of cancer in the United
States is projected to be about 2 million in the year 2020 [8,9]. The number of metal-based complexes
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Staurosporine ligands coordinated with ruthenium have been studied as protein kinase
inhibitors [25]. The R-enantiomer was a more potent inhibitor exhibiting a more than 250-fold
increase in comparison to the S-enantiomer [25]. Ru(II) arene chiral complexes have also been studied,
with the R,S or S,R isomers showing higher cytotoxicity than the R,R or S,S compounds in human
ovarian cancer cell line A2780 [26]. Other chiral organometallic complexes that have been studied for
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Scheme
2.
Scheme 1.
1. Synthesis of (a) 11 and (b) 2.

2.2. X-ray Crystallography
Crystals of 2 were grown by slow diffusion of ether into a concentrated DCM solution of gold
complex and analyzed by X-ray diffraction. The unique structure of 2 which occurs as the S,S-QuinoxP*
ligand reacts with two molar equivalents of HAuCl4 ·3H2 O (Scheme 1) crystallizes as a monocationic
complex in a triclinic crystal system with P1 space group (Figure 2). The X-ray structure of 2 reveals

91.8(2), indicating a square planar geometry. The stereochemistry was determined by placing the
ellipsoid diagram of complex 2 in the plane using the Mercury program [41]. The X-ray Parameters
of 2 is shown in Table 2.
Table 1. Selected interatomic distances (Å) and angles (deg) from the crystal structure of complex 2,
4 of 13
shown in Figure 2.
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a C2 -symmetric square-planar geometry around the gold centre, with two t-butylmethyl phosphine
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Å
8
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4 ·3H2 O defining the d Au(III)
Au1A-P1A
2.298(6) Å
geometry, as shown in Figure 2. The bond length (Table 1) of the Au-P bond is Au1A-P2A: 2.292(6) Å
Au1A-Cl2A
2.320(6) Å
and Au1A-P1A: 2.298(6) Å, while the Au-Cl bond is Au1A-Cl2A: 2.320(6) Å and Au1A-Cl1A: 2.327(6) Å.
Au1A-Cl1A
2.327(6) Å
The bond angle for the P2A-Au1A-P1A is 89.4(2)◦ and Cl2A-Au1A-Cl1A is 91.8(2), indicating a square
P2A-Au1A-P1A
89.4(2)°
planar geometry. The stereochemistry was determined by placing the ellipsoid diagram of complex 2
Cl2A-Au1A-Cl1A
91.8(2) °
in the plane using the Mercury program [41]. The X-ray Parameters of 2 is shown in Table 2.

Figure 2. X-ray crystal structure of complex 2. Depicted above is the full unit cell; two cations and two
Figure 2. X-ray crystal
structure
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2. Depicted
is the level.
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cell; twoatoms
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andbeen
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All of
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at 50%above
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Hydrogen
have
tetrachloroaurate(III)
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been omitted for clarity.
Table 1. Selected interatomic distances (Å) and angles (deg) from the crystal structure of complex 2,
shown in Figure 2.
Selected Atom

Selected Atomic Distances (Å) and Angles (◦ )

Au1A-P2A
Au1A-P1A
Au1A-Cl2A
Au1A-Cl1A
P2A-Au1A-P1A
Cl2A-Au1A-Cl1A

2.292(6) Å
2.298(6) Å
2.320(6) Å
2.327(6) Å
89.4(2)◦
91.8(2)◦

Table 2. X-ray Parameters of 2.
X-ray Structural Data and Crystal Refinement
Empirical Formula
Molecular Weight (g/mol)
Temperature (K)
X-ray Radiation (Å)
Crystal System, Space Group
Unit Cell Dimensions (A), (o)
Volume
Z
Absorption Coefficient
F(000)
Crystal Size (mm)
Theta Range
Completeness to Theta = 25.242
F2
Final R indices [I > 2sigma(I)]

C18 H28 Au2 Cl6 N2 P2
941.00
90.0(2)
Mo Kα (0.71073 Å)
Triclinic, P1
a = 11.0642(4) Å alpha = 80.985(1)
b = 11.2636(4) Å beta = 83.150(1)
c = 12.5182(4) Å gamma = 63.674 (1)
1378.79(8) Å3
2
11.336 mm−1
880
0.120 × 0.040 × 0.030
2.031 to 27.512
100%
1.022
R1 = 0.0518, wR2 = 0.1258
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2.3. Biological Stability of 1 and 2
2.3.1. UV–Vis Stability in Biological Media
We first carried out stability studies on 1 and 2 in two biological media—Dulbecco’s modified
eagle medium (DMEM) and Roswell Park Memorial Institute-1640 (RPMI-1640); both DMEM and
RPMI-1640 contains large amount of amino acids, glucose, and other biological nucleophiles. This is
important as anticancer drugs should be stable and not decompose before reaching their intracellular
targets. Gold complexes, in particular Au(III) complexes, are highly susceptible to reduction by
biological nucleophiles [42–44], especially cysteine containing residues. The stability of complexes in
biological medium is pertinent to the efficacy and longevity of the chemotherapeutic in question [44].
The two complexes (1 and 2) were observed for a period of 48 h in biological buffer solutions at
37 ◦ C to mimic the body temperature. Both 1 and 2 exhibited great stability in both DMEM and
RPMI-1640 over the course of the experiment (Figure 3). Given that most complexes are cleared
within 60–80 min [45], the relative high stability of these complexes makes them a great framework for
gold(III) chemotherapeutic development. The high-energy bands and intense absorption observed in
the UV–vis spectra of 1 and 2 in RPMI at 247 and 322 nm may be attributed to the ligand-to-metal
charge transfer (LMCT) or metal-to-ligand charge-transfer (MLCT) character of the Au(III) center.
There was no change in the absorption profile of 1 or 2 in RPMI 1640 and a slight change in DMEM.
The stability of 1 and 2 in RPMI can be attributed to the Au-P bonds that enhance sigma-donation to
the gold center. The slight hump at 568 nm in the spectra of 1 and 2 in DMEM can be attributed to
Molecules 2020, 25,
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Reaction of 1 and 2 with GSH in ratio 1:1 or 1:10 did not alter the absorption bands associated
with the gold complexes, suggestive of high compound stability in GSH. The UV–vis absorption band
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reacted with protein hen egg white lysozyme (HEWL) [43]. Additionally, activation of the gold center
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center is believed to take place via the displacement of the labile chloride atom without alteration of
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Reaction of 1 and 2 with GSH in ratio 1:1 or 1:10 did not alter the absorption bands associated
with the gold complexes, suggestive of high compound stability in GSH. The UV–vis absorption band
with the gold complexes, suggestive of high compound stability in GSH. The UV–vis absorption band
at 242 and 330 nm may be as a result of ligand-to-metal charge transfer (LMCT) or metal-to-ligand
at 242 and 330 nm may be as a result of ligand-to-metal charge transfer (LMCT) or metal-to-ligand
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charge-transfer (MLCT). Additionally, there is also a possibility of the displacement of the chloride
ions by GSH in 1 and 2, which is seen at a higher concentration with the absorption band at 430 nm,
ions by GSH in 1 and 2, which is seen at a higher concentration with the absorption band at 430 nm,
yet it is clear that the compound is not reduced to elemental gold in the biological media (Figure 4.
yet it is clear that the compound is not reduced to elemental gold in the biological media (Figure 4.
The solution studies suggest that 1 and 2 are not decomposed in biological nucleophiles and hence
The solution studies suggest that 1 and 2 are not decomposed in biological nucleophiles and hence
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2.4. Cytotoxicity of 1 and 2
The antiproliferative activity of the two complexes was compared against the ligands
(R,R-QuinoxP* and S,S-QuinoxP*, auranofin, cisplatin by monitoring the inhibition of cell growth
using a crystal violet assay. The cytotoxic activity was determined in three human cancer cell
lines—MDA-MB-468 triple negative breast cancer cell (TNBC), HCC1937 breast cancer cell line (TNBC)
and H460 lung cancer cell line. The IC50 values were extrapolated from dose–response curves, and these
results have been summarized in Table 3 and Figure 5. Compounds 1 and 2 were cytotoxic in all the cell
lines studied. They exhibited higher cytotoxicity in the TNBC cell line, MDA-MB-468 studied with an
IC50 of 1.51 and 1.08 µM compared to their respective ligands, auranofin and cisplatin. The cytotoxicity
of 1 and 2 in the lung cancer cell line (H460) was slightly lower than that of cisplatin and auranofin.
The cytotoxicity observed in these complexes makes them possible candidates as gold-based anticancer
agents. It is noteworthy to say that the two novel complexes do not show a marked difference in
cytotoxicity compared to other enantiomeric complexes.
Table 3. In vitro antiproliferative activity. IC50 values for 1 and 2 across a panel of cell lines. Cells were
seeded at a density of 2000 cells per well and treated for 72 h. IC50 values are plotted as the mean ±
s.e.m (n = 3).
IC50 (µM)

MDA-MB-468
H460
HCC1937

1

2

R,R
QuinoxP*

S,S
QuinoxP*

Cisplatin

Auranofin

1.51 ± 0.07
4.53 ± 0.09
4.83 ± 0.1

1.08 ± 0.13
4.53 ± 0.06
3.85 ± 0.08

14.8 0 ± 1.03
11.75 ± 1.40
-

14.80 ± 1.03
11.75 ± 1.40
-

2.09 ± 0.19
1.41 ± 0.12
105.98 ± 0.97 a

1.31 ± 0.09
1.69 ± 0.21
-

a

= Reported IC50 of cisplatin in HCC1937 [51].

MDA-MB-468
H460
HCC1937
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1
1.51 ± 0.07
4.53 ± 0.09
4.83 ± 0.1

2
1.08 ± 0.13
4.53 ± 0.06
3.85 ± 0.08
a

IC50 (µM)
R,R QuinoxP* S,S QuinoxP* Cisplatin Auranofin
14.8 0 ± 1.03
14.80 ± 1.03
2.09 ± 0.19 1.31 ± 0.09
11.75 ± 1.40
11.75 ± 1.40
1.41 ± 0.12 1.69 ± 0.21
105.98 ± 0.97 a

= Reported IC50 of cisplatin in HCC1937 [51].
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used
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4 ·3H
and stored under nitrogen atmosphere. R,R-QuinoxP* and S,S-QuinoxP* were purchased from Strem
Chemicals. Deuterated solvents were purchased from Cambridge Isotope Laboratories (Andover,
MA, USA). NMR spectra were recorded on a Bruker Avance NEO 400 MHz spectrometer and
samples calibrated for: 1H NMR (CDCl3 δ = 7.26 ppm), 13C NMR (CDCl3 δ = 77.16) and 31P NMR
externally referenced to H3PO4 δ = 0.00. High-resolution mass spectra (HRMS) were obtained by
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Partz and stored under nitrogen atmosphere. R,R-QuinoxP* and S,S-QuinoxP* were purchased
from Strem Chemicals. Deuterated solvents were purchased from Cambridge Isotope Laboratories
(Andover, MA, USA). NMR spectra were recorded on a Bruker Avance NEO 400 MHz spectrometer
and samples calibrated for: 1 H NMR (CDCl3 δ = 7.26 ppm), 13 C NMR (CDCl3 δ = 77.16) and 31 P NMR
externally referenced to H3 PO4 δ = 0.00. High-resolution mass spectra (HRMS) were obtained by direct
flow injection (injection volume = 2 µL) using ElectroSpray Ionization (ESI) on a Waters Synapt G2
HDMS instrument in the positive mode with a quadripole/TOF analyzer (UC Boulder). Elemental
analysis results were obtained from Atlantic Microlabs, Inc (Norcross, GA, USA). In addition to
spectroscopic characterization, the purity of all compounds was assessed by reverse phase high
performance liquid chromatography (RP-HPLC) using an Agilent Technologies 1100 series HPLC
instrument and an Agilent Phase Eclipse Plus C18 column (4.6 × 100 mm; 3.5 µm particle size).
All compounds were found to be ≥ 97% pure.
3.2. Synthesis of Compounds 1 and 2
Synthesis of [((R,R)-(–)-2,3-Bis(tert-butylmethylphosphino)quinoxaline)AuCl2 ][AuCl4 ] (1):
HAuCl4 ·3H2 O (91.87 mg, 0.233 mmol) was dissolved in DCM (2 mL) and R,R-[2,3bis(tert-butylmethylphosphino)quinoxaline (39 mg, 0.117 mmol) was dissolved in 2 mL of DCM
which was added dropwise. The reaction mixture turned red while adding and the mixture was left
to stir at room temperature until the color changed to light orange after 45 min. The reaction was
filtered through celite, concentrated in vacuo, and the compound precipitated with ether to yield a
yellow colored solid. Yield: 40 mg, (36.4%). 1 H NMR (400 MHz, CDCl3 ) 8.55 (dd, J = 6.4, 3.6 Hz, 2H),
8.31 (dd, J = 6.8, 3.6 Hz, 2H), 2.79 (d, J = 16 Hz, 6H), 1.51 (d, J = 20 Hz, 18H); 13 C NMR (101 MHz,
CDCl3 ) δ = 146.46, 137.11, 130.97, 65.87, 28.23, 15.29; 31 P NMR (162 MHz, DMSO-d6 ) δ = 70.28. HRMS
(m/z) calcd. 601.0770, found 601.0781 [M − AuCl4 ]+ (Figures S7 and S8). Elemental analysis calcd.
%C 22.97, %H 3.00, %N 2.98; found %C 23.24, %H 3.07, %N 3.10. Purity was determined to be >97% by
RP-HPLC: Rf = 9.33 min using the following method: Flow rate: 1 mL/min; λ = 280 nm; Eluent A = H2 O
with 0.1% TFA; Eluent B = MeCN with 0.1% Formic acid; Solvent Gradient: 0–7 min (70:30 H2 O:MeCN),
5 min (50:50 H2 O:MeCN), 10 min (100 MeCN) and 15 min (20:80 H2 O:MeCN).
Synthesis of [((S,S)-(+)-2,3-Bis(tert-butylmethylphosphino)quinoxaline)AuCl2 ][AuCl4 ] (2):
HAuCl4 ·3H2 O (91.87 mg, 0.233 mmol) was dissolved in DCM (2 mL) and S,S-[2,3bis(tert-butylmethylphosphino)quinoxaline (37 mg, 0.111 mmol) dissolved in 2 mL of DCM was
added dropwise, the reaction mixture turned red while adding and the mixture was left to stir at room
temperature until the color changed to light orange after 45 min. The reaction was filtered through
celite, concentrated in vacuo, and the compound precipitated with ether to yield a yellow colored solid.
Yield: 40 mg, 41.5%). 1 H NMR (400 MHz, CDCl3 ) 8.54 (dd, J = 8, 3.2 Hz, 2H), 8.29 (dd, J = 6, 2.8, Hz, 2H),
2.77 (d, J = 16 Hz, 6H), 1.48 (d, J = 20 Hz, 18H); 13 C NMR (101 MHz,CDCl3 ) δ = 143.25, 137.03, 130.34,
41.38, 28.08, 7.72; 31 P NMR (162 MHz, DMSO-d6 ) δ = 70.45. HRMS (m/z) calcd. 601.0770, found
601.0781 [M – AuCl4 ]+ (Figures S11 and S12). Elemental analysis (%) calcd. %C 22.97, %H 3.00,
%N 2.98; Found %C 23.12, %H 3.01, %N 3.04. Purity was demonstrated to be >97% by RP-HPLC:
Rf = 10.4 min using the following method: Flow rate: 1 mL/min; λ = 280 nm; Eluent A = H2 O with
0.1% TFA; Eluent B = MeCN with 0.1% Formic acid; Solvent Gradient: 0–7 min (70:30 H2 O:MeCN),
5 min (50:50 H2 O:MeCN), 10 min (100 MeCN) and 15 min (20:80 H2 O:MeCN).
3.3. Physical and Chemical Characterization
3.3.1. X-ray Crystallography
Crystals of complex 2 were grown from slow diffusion of Et2 O into a concentrated solution of
MeCN at room temperature. All crystals were mounted using polyisobutene oil on the end of a glass
fiber, which had been mounted to a copper pin using an electrical solder. It was placed directly in
the cold gas stream of a liquid nitrogen cryostat [53,54]. A Bruker D8 Venture diffractometer with
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graded multilayer focused MoKα X-rays (λ = 0.71073 Å) was used to collect diffraction. Raw data
were integrated, scaled, merged and corrected for Lorentz-polarization effects using the APEX3
package [55–57]. Space group determination and structure solution and refinement were carried out
with SHELXT and SHELXL, respectively [58,59]. All non-hydrogen atoms were refined with anisotropic
displacement parameters. Hydrogen atoms were placed at calculated positions and refined using a
riding model with their isotropic displacement parameters (Uiso) set to either 1.2Uiso or 1.5Uiso of the
atom to which they were attached. Ellipsoid plots were drawn using SHELXTL-XP [60]. The structures,
deposited in the Cambridge Structural Database, were checked for missed symmetry, twinning and
overall quality with PLATON, [61] an R-tensor, [62] and finally validated using CheckCIF [61].
3.3.2. UV–Vis Stability
DMEM and RPMI-1640 were purchased from Corning Inc. and used without further supplements.
Spectra were recorded on a Shimadzu-1280 spectrophotometer. Prior to use, the media were warmed
to 37 ◦ C and incubated at that temperature throughout the course of the experiment. The complexes
were prepared as 1 mM stock in DMSO and subsequently diluted to a final concentration of 50 µM
in each respective medium. No precipitation of colloidal gold was observed. During the course
of the experiment, the gold containing solutions were kept in an incubator at 37 ◦ C to mimic
biological conditions. Prior to each scan, the instrument was blanked with the corresponding medium.
The UV–vis spectra were then recorded at various time intervals (total time = 48 h) to compare longevity
of the complex.
3.3.3. Cyclic Voltammetry of 2
Electrochemical measurements of the ligands were recorded with a scan rate of 0.1 V/s with a
three-segment sweep and a sample interval of 0.001 V. The quiet time was set to 2 s and sensitivity and
1 × 10−4 A/V. All solutions were freshly prepared prior to use. All spectra were recorded using a CH
instruments 650E potentiostat. The electrodes used were all 3 mm: glassy carbon working electrode
(CHI104), Ag/AgCl reference electrode (CHI111) and a platinum wire counter electrode (CHI115).
Compound 2 as well as S,S-[2,3-bis(tert-butylmethylphosphino)quinoxaline] were prepared as a 5 mM
solution in dry MeCN with NBu4 PF6 (0.1 M) as the supporting electrolyte. The samples were purged
with nitrogen for 30 min and recorded. Data were analyzed with GraphPad Prism6.
3.4. In Vitro Biological Assays
3.4.1. Cell Culture
All cell lines were purchased from ATCC and routinely grown in a humidified incubator at 37 ◦ C
with 5–10% CO2 . MDA-MB-468 were grown in DMEM supplemented with 10% FBS, 1% amphotericin
and 1% penicillin/streptomycin. H460, and HCC1937 cells were grown in RPMI supplemented with
10% FBS, 1% amphotericin and 1% penicillin/streptomycin, as well as 4 mM glutamine. All supplements
along with PBS and trypsin-ethylenediaminetetraacetic acid (trypsin-EDTA) were purchased from
Corning Inc. and used as is.
3.4.2. Cell Viability of 1 and 2
The cell viabilities of 1 and 2, were determined in MDA-MB-468, H460 and HCC1937. Additionally,
cisplatin, auranofin and both S,S and R,R-QuinoxP* were determined in MDA-MB-468 and H460.
Cells were grown to confluency and trypsin was added to detach and harvest cells. The cells were
washed with 2 mL of PBS and suspended in 10 mL of the appropriate media. The cells were centrifuged
at 2000 rpm for 5 min and the pellet washed with 2 mL of PBS then suspended in 5 mL of the
appropriate media. The cells were plated at a density of 2000 cells/well in a 96-well clear bottom
plate and allowed to adhere overnight at 37 ◦ C with 5–10% CO2 . The compounds were prepared
as a stock in DMSO and used fresh. The compounds were added at seven concentrations with a
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3× serial dilution starting at 50 µM for the highest concentration and incubated at 37 ◦ C for 72 h with
5–10% CO2 . The cells were fixed with 1% glutaraldehyde (in PBS) and staining with 0.5% crystal
violet, as previously described [15]. The plates were read using a Genios plate reader (λ = 570 nm).
The experiment was performed in triplicate and data are plotted as the mean ± s.e.m. (n = 3).
3.4.3. Reactivity of 1 and 2 with L-GSH
Interactions between 1 and 2 were performed via monitoring with UV–vis spectrometry on a
Shimadzu-1280 spectrophotometer. Solutions of 1 and 2 were prepared similarly to the stability studies.
A 50 µM solution of both compounds were prepared in RPMI-1640 that was pre-warmed to 37 ◦ C.
The compounds were run alone and recorded as a concentration 0 µM addition of L-GSH. L-GSH was
then added portion-wise to the solution to achieve 50 µM and the spectrum recorded. L-GSH was
added portion-wise to achieve a concentration of 500 µM and the subsequent spectrum was recorded.
4. Conclusions
Two new compounds (R,R)-(–)-2,3-Bis(tert-butylmethylphosphino)quinoxalinedichlorogold(III)
tetrachloroaurates(III) and (S,S)-(+)-2,3-Bis(tert-butylmethylphosphino)quinoxalinedichlorogold(III)
tetrachloroaurates(III) were synthesized and found to be cytotoxic in three cancer cell lines tested.
With an IC50 of 1.51 µM and 1.08 µM for 1 and 2 in MDA-MB-468 triple negative breast cancer
cell line, these compounds compare well with cisplatin (IC50 = 2.09 µM) and auranofin (1.312 µM).
Their cytotoxicity in H460 and HCC1937 is slightly higher than that of cisplatin and auranofin.
The X-ray crystal structure of 2 shows that the geometry around the gold center is square planar and
the electrochemical studies and reaction with GSH shows that the compounds are stable as it does not
decompose within the period under investigation. The stability of the two compounds in biological
media and promising antiproliferative potential places these compounds as candidates for therapeutic
development. Further biological characterization of 1 and 2 needs to be carried out to investigate their
selectivity to normal cells and potential biological target(s) or mechanism of action.
Supplementary Materials: The following are available online, NMR spectra of 1 and 2 (Figures S1–S6); HRMS data
of 1 and 2 (Figures S7–S14); HPLC data (Figures S15 and S16); Electrochemistry (Figure S17) and Accession Code.
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